Minaprine

Summary

Minaprine (CHEMBL278819) is an approved small-molecule antidepressant (ATC N06AX07); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX07
• Indications: 1 condition
• Chemistry: 298.4 Da · C17H22N4O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL278819
Name	Minaprine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4199
ChEBI	CHEBI:51038
ATC	N06AX07
Molecular formula	C17H22N4O
Molecular weight	298.4
InChIKey	LDMWSLGGVTVJPG-UHFFFAOYSA-N

SMILES: CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3

IUPAC name: 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine

Pharmacological roles (ChEBI): antidepressant, serotonin uptake inhibitor, dopamine uptake inhibitor, cholinergic drug, antiparkinson drug.

Also known as: AGR-1240, Brantur, CB-30038, Minaprina, Minaprine, SID11112706, MINAPRINE, minaprine

Parent form; salt/anhydrous children: CHEMBL536932, CHEMBL1364551

Patent coverage: 865 distinct patent families (3,320 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Inositol monophosphatase 1, 5-hydroxytryptamine receptor 2B, Muscarinic acetylcholine receptor M1, Cannabinoid receptor 1, Acetylcholinesterase, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M1, Cytochrome P450 2D6, Androgen receptor.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P97697	8.6	Potency	2.5	nM	CHEMBL_ACT_4828720
TDP1	7.95	Potency	11.2	nM	CHEMBL_ACT_3928437
HTR2B	5.86	AC50	1396	nM	CHEMBL_ACT_25164049
KCNH2	5.46	AC50	3436	nM	CHEMBL_ACT_25117550
HTR2B	5.27	AC50	5400	nM	CHEMBL_ACT_25227327
CYP2D6	5.1	Potency	7943	nM	CHEMBL_ACT_4986110
CYP2D6	5.1	AC50	7943	nM	CHEMBL_ACT_6062988
CNR1	5.02	AC50	9497	nM	CHEMBL_ACT_25181506
P15207	5.01	AC50	9740	nM	CHEMBL_ACT_25187333
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4961472
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5030721
CYP3A4	5	AC50	10000	nM	CHEMBL_ACT_6031597
CYP1A2	5	AC50	10000	nM	CHEMBL_ACT_6034097

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).